Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
Daniel Barber
person3 mentionslast seen Oct 14, 2026
President and Chief Executive Officer of Aquestive Therapeutics.
Relationships 1
Relationship
Aquestive Therapeutics, Inc.employsDaniel Barber
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGAROct 14, 2026Aquestive Therapeutics, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 9.01: Financial Statements and Exhibits
Daniel Barber, President and Chief Executive Officer of Aquestive Therapeutics
- filingSEC EDGAROct 14, 2026Eton Pharmaceuticals, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.01: Completion of Acquisition or Disposition of Assets; Item 9.01: Financial Statements and Exhibits
Daniel Barber, President and Chief Executive Officer of Aquestive Therapeutics
- filingSEC EDGARSep 17, 2026Aquestive Therapeutics, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Daniel Barber, President and Chief Executive Officer of Aquestive Therapeutics